Administration of G-CSF or GM-CSF theoretically may increase the prevalence of adverse events which include immunologically mediated organ dysfunction, such as acute respiratory distress syndrome (ARDS), to which patients with severe sepsis are particularly prone [49]. This evidence concerns the gene CSF3 and Sepsis.